Albumedix Ltd. ( ́Albumedix ́), a recognized leader in recombinant human albumin-based solutions, today announced that it has entered into a definitive agreement to be acquired by life science group Sartorius, an international leader in laboratory and bioprocessing technologies for the biopharmaceutical industry. Through this acquisition, Albumedix and Sartorius expand their solution space with complementary technologies and synergetic competencies, to deliver science-enabled solutions for the entire advanced therapy value chain.